BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Syrogiannopoulos GA, Michoula AN, Tsimitselis G, Vassiou K, Chryssanthopoulou DC, Grivea IN. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine. Infectious Diseases 2016;48:749-53. [DOI: 10.1080/23744235.2016.1192720] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Levy C, Biscardi S, Dommergues MA, Dubos F, Hees L, Levieux K, Aurel M, Minodier P, Zenkhri F, Cohen R; Pneumonia study group. Impact of PCV13 on community-acquired pneumonia by C-reactive protein and procalcitonin levels in children. Vaccine 2017;35:5058-64. [PMID: 28778617 DOI: 10.1016/j.vaccine.2017.06.057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
2 Díaz‐conradi A, Hernández S, García‐garcía JJ, Muñoz‐almagro C, Moraga‐llop F, Ciruela P, Izquierdo C, Campins M, de Sevilla MF, González‐peris S, Uriona S, Martínez‐osorio J, Solé‐ribalta A, Codina G, Esteva C, Planes AM, Soldevila N, Salleras L, Domínguez A. Complicated pneumococcal pneumonia with pleural effusion or empyema in the 13‐valent pneumococcal conjugate vaccine era. Pediatr Pulmonol 2019;54:517-24. [DOI: 10.1002/ppul.24279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
3 Principi N, Esposito S. Prevention of Community-Acquired Pneumonia with Available Pneumococcal Vaccines. Int J Mol Sci 2016;18:E30. [PMID: 28029140 DOI: 10.3390/ijms18010030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
4 Triadou D, Givon-Lavi N, Greenberg D, Ben-Shimol S. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016. Infect Dis (Lond) 2020;52:186-95. [PMID: 31774020 DOI: 10.1080/23744235.2019.1695060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 González-peris S, Campins M, García-garcía JJ, Díaz-conradi Á, Domínguez Á, Ciruela P, de Sevilla MF, Hernández S, Muñoz-almagro C, Izquierdo C, Codina G, Uriona S, Esteva C, Solé-ribalta A, Soldevila N, Planes AM, Martínez-osorio J, Salleras L, Moraga-llop F. Necrotizing pneumonia due to Streptococcus pneumoniae in children during the period of non-systematic use of PCV13 in Catalonia, Spain. Enfermedades Infecciosas y Microbiología Clínica 2020. [DOI: 10.1016/j.eimc.2020.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Alarcón ZK, Duarte C, Sanabria O, Moreno J. Streptococcus pneumoniae serotype 3 genotypes in invasive isolates from Colombia. Biomedica 2021;41:338-46. [PMID: 34214273 DOI: 10.7705/biomedica.5407] [Reference Citation Analysis]
7 Rix-Trott K, Byrnes CA, Gilchrist CA, Matsas R, Walls T, Voss L, Mahon C, Dickson NP, Reed P, Best EJ. Surveillance of pediatric parapneumonic effusion/empyema in New Zealand. Pediatr Pulmonol 2021;56:2949-57. [PMID: 34232567 DOI: 10.1002/ppul.25564] [Reference Citation Analysis]
8 Principi N, Esposito S. Pneumococcal Disease Prevention: Are We on the Right Track? Vaccines (Basel) 2021;9:305. [PMID: 33804822 DOI: 10.3390/vaccines9040305] [Reference Citation Analysis]
9 Hon KL, Chan KH, Ko PL, Cheung MHY, Tsang KYC, Chan LCN, Chan RWY, Leung TF, Ip M. Change in Pneumococcus Serotypes but not Mortality or Morbidity in Pre- and Post-13-Valent Polysaccharide Conjugate Vaccine Era: Epidemiology in a Pediatric Intensive Care Unit over 10 Years. J Trop Pediatr 2018;64:403-8. [PMID: 29126217 DOI: 10.1093/tropej/fmx084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Liese J, Schoen C, van der Linden M, Lehmann L, Goettler D, Keller S, Maier A, Segerer F, Rose M, Streng A. Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study. Clinical Microbiology and Infection 2019;25:857-64. [DOI: 10.1016/j.cmi.2018.10.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
11 Moreira M, Castro O, Palmieri M, Efklidou S, Castagna S, Hoet B. A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016). Hum Vaccin Immunother 2017;13:1-12. [PMID: 27996380 DOI: 10.1080/21645515.2016.1263409] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
12 Strachan R, Homaira N, Beggs S, Bhuiyan MU, Gilbert GL, Lambert SB, Macartney K, Marshall H, Martin AC, McCallum GB, McCullagh A, McDonald T, McIntyre P, Oftadeh S, Ranganathan S, Suresh S, Wainwright CE, Wilson A, Wong M, Snelling T, Jaffé A. Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia. Thorax 2021;76:487-93. [PMID: 33504566 DOI: 10.1136/thoraxjnl-2020-216032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Wiese AD, Griffin MR, Zhu Y, Mitchel EF Jr, Grijalva CG. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era. Vaccine 2016;34:6243-9. [PMID: 27832918 DOI: 10.1016/j.vaccine.2016.10.062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
14 Le Saux NMA, Bowes J, Viel-Thériault I, Thampi N, Blackburn J, Buba M, Harrison MA, Barrowman N. Combined influence of practice guidelines and prospective audit and feedback stewardship on antimicrobial treatment of community-acquired pneumonia and empyema in children: 2012 to 2016. Paediatr Child Health 2021;26:234-41. [PMID: 34136053 DOI: 10.1093/pch/pxaa066] [Reference Citation Analysis]
15 Levy C, Varon E, Ouldali N, Béchet S, Bonacorsi S, Cohen R. Changes in Invasive Pneumococcal Disease Spectrum After 13-Valent Pneumococcal Conjugate Vaccine Implementation. Clinical Infectious Diseases 2019. [DOI: 10.1093/cid/ciz221] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Zimmermann P, Perrett KP, Berbers G, Curtis N. Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccine. Arch Dis Child 2019;104:680-4. [PMID: 30796020 DOI: 10.1136/archdischild-2018-316254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Nieddu F, Moriondo M, De Vitis E, Ricci S, Indolfi G, Resti M, Vocale C, Landini MP, Sartor A, Azzari C. PCV13 serotype decrease in Italian adolescents and adults in the post-PCV13 era: Herd protection from children or secular trend? Vaccine 2017;35:1544-50. [DOI: 10.1016/j.vaccine.2017.01.064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
18 Esposito S, Dal Canto G, Caramia MR, Fainardi V, Pisi G, Principi N. Complications in community acquired pneumonia: magnitude of problem, risk factors, and management in pediatric age. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 33971782 DOI: 10.1080/14787210.2021.1927710] [Reference Citation Analysis]
19 Silva-Costa C, Brito MJ, Pinho MD, Friães A, Aguiar SI, Ramirez M, Melo-Cristino J; Portuguese Group for the Study of Streptococcal Infections., Portuguese Study Group of Invasive Pneumococcal Disease of the Pediatric Infectious Disease Society. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015. Emerg Infect Dis 2018;24:1307-14. [PMID: 29912700 DOI: 10.3201/eid2407.180029] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
20 Haji T, Byrne A, Kovesi T. Trends in Pediatric Complicated Pneumonia in an Ontario Local Health Integration Network. Children (Basel) 2018;5:E36. [PMID: 29510484 DOI: 10.3390/children5030036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Madhi F, Levy C, Morin L, Minodier P, Dubos F, Zenkhri F, Dommergues MA, Mezgueldi E, Levieux K, Béchet S, Varon E, Cohen R; Pneumonia Study Group ., GPIP (Pediatric Infectious Disease Group) . Change in Bacterial Causes of Community-Acquired Parapneumonic Effusion and Pleural Empyema in Children 6 Years After 13-Valent Pneumococcal Conjugate Vaccine Implementation. J Pediatric Infect Dis Soc 2019;8:474-7. [PMID: 30407519 DOI: 10.1093/jpids/piy103] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
22 Zampoli M, Chaya S, Zar HJ. Empyema in Children: Update of Aetiology, Diagnosis and Management Approaches. Curr Pulmonol Rep 2017;6:16-25. [DOI: 10.1007/s13665-017-0161-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]